

Prenatal and neonatal screening of haemoglobinopathies: a prospective study

Submission date 28/04/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 28/04/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 02/09/2008	Condition category Haematological Disorders	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr J.L.H. Kerkhoffs

Contact details
HagaHospital
Leyweg 275
The Hague
Netherlands
2545 CH
+31 (0)70 3592004
J.Kerkhoffs@hagaziekenhuis.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
METC-nr 05-83; NTR622

Study information

Scientific Title

Study objectives

The carrier frequency of haemoglobinopathies is greater than 0.05 and screening for primary prevention is cost-effective.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Study design

Cross sectional study

Primary study design

Observational

Secondary study design

Cross-section survey

Study setting(s)

Not specified

Study type(s)

Screening

Participant information sheet

Health condition(s) or problem(s) studied

Haemoglobinopathies

Interventions

Unselected group of pregnant females (n = 1000) and a group of newborns (n = 1000) will be screened for haemoglobinopathies.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Carrier frequency of haemoglobinopathies.

Secondary outcome measures

1. Serum ferritin
2. Compliance to prenatal testing
3. Cost-effectiveness

Overall study start date

01/03/2006

Completion date

28/02/2007

Eligibility

Key inclusion criteria

1. Pregnant females before the 16th week of pregnancy and newborns
2. Informed consent

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

2000

Key exclusion criteria

Known haemoglobinopathy

Date of first enrolment

01/03/2006

Date of final enrolment

28/02/2007

Locations

Countries of recruitment

Netherlands

Study participating centre

HagaHospital

The Hague

Netherlands

2545 CH

Sponsor information

Organisation

HagaZiekenhuis (The Netherlands)

Sponsor details

Leyweg 275

The Hague

Netherlands

2545 CH

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/03q4p1y48>

Funder(s)

Funder type

Research organisation

Funder Name

The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration